Oxidative stress plays an important role in the development of renal damage in diabetes and hypertension. The major source of oxidative stress is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-derived superoxide anion (O 2 .-) that directly damage cell and also activate signaling of cell proliferation, adhesion molecules, and fibrosis. O 2 .
INTRODUCTION
There are many types of radicals, but those of most concern in biological systems derive from oxygen, and are named reactive oxygen species (ROS). The most important ROS is superoxide anion (O 2 .- ) that can itself exert effects on cellular function or can be converted into other radicals playing a central role in the generation of ROS. Several enzymes like nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, mitochondrial electron transport chain, lipoxygenase, cyclooxygenase, cytochrome P450, xanthine oxidase, nitric oxide synthase (NOS), use oxygen as an acceptor of electron transfer and generate ROS. In the kidney NADPH oxidase has been shown the main source of O 2 -generation because blockade of xanthine oxidase and mitochondrial electron transport chain had a minor effect on O 2 .-generation in podocytes [1] .
Enhanced ROS has been focused as a common denominator in the pathogenesis of hypertension, diabetes, and hypercholesterolemia. In this review we will focus on the production of O 2 .
-by NADPH oxidase in the kidney in hypertension and diabetes and the renoprotective effect of NADPH oxidase suppression and enhancement of nitric oxide (NO) bioavailability.
NADPH OXIDASE STRUCTURE AND SPECIFIC FEATURES OF NON-PHAGOCYTIC NADPH OXIDA-SES
The structure and function of NADPH oxidase were first described and characterized in neutrophils. Phagocytic NADPH oxidase is comprised of two membrane components *Address correspondence to this author at the Division of Nephrology and Endocrinology, Department of Internal Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; Tel: +81-3-3815-5411; Ext. 33056; Fax: +81-3-3814-0021; E-mail: tojyo-2im@h.u-tokyo.ac.jp gp91phox (phox standing for phagocytic oxidase) and p22phox, that constitutes the cytochrome b558, and four cytoplasmic subunits, p47phox, p67phox, p40phox and the small GTP-binding protein Rac [2] . When activated the cytosolic subunit p47phox phosphorilates, and assemblies with the other cytoplasmic subunits, and this complex translocates to the membrane subunits, and will initiate the respiratory burst cascade [2, 3] , (Fig. 1) .
Although non-phagocytic NADPH oxidase is quite similar to the phagocytic NADPH oxidase, there are several distinct features that allow differentiation between both oxidases. O 2 .-production by non-phagocytic NADPH oxidases occurs continuously and at low rates (nanomolar range) in contrast to the phagocytic NADPH oxidases that release O 2 .-at high rates (micromolar range) in bursts [2] . The activation of the non-phagocytic NADPH oxidases occurs in minutes to hours while in leukocytes it occurs in seconds [2, 3] . In the past few years homologues of gp91phox (also named Nox2) have been described in the non-phagocytic NADPH oxidase system, and based in their homologies to each other named Nox1 (previously named Mox1), Nox3, Nox4 and Nox5 and two longer homologues Duox1 and Duox2 (Table 1) [4, 5] .
EXPRESSION OF NADPH OXIDASE SUBUNITS IN THE KIDNEY
Sumimoto H et al. [6] were the first to detect the mRNA of cytochrome b558 in the kidney followed by Neale et al that found increased cytochrome b558 β-subunit (gp91phox) in podocytes, mesangial cells and endothelial cells in passive Heyman nephritis [7] and Jones et al. that detected protein and mRNA for p47phox, p67phox, and p22phox in human glomerular mesangial cells [8] . We performed immunohistochemical study of NADPH oxidase subunits in the spontaneously hypertensive rat (SHR) kidney and we found that p22phox, p47phox, and p67phox are expressed in the renal vasculature, in the apical region of the macula densa (MD) cells, cortical thick ascending limbs (TAL), distal convoluted tubules (DCT), and cortical collecting ducts (CCD). Nox4 (also called RENOX) [9] is expressed in the DCT, weakly in the proximal tubule and in the glomeruli [10] , ( Table 1 ). In the glomeruli p47phox is expressed in podocytes and weakly in glomerular endothelial cells [11, 12] . It is believed that the localization of NADPH oxidase subunits in the MD, TAL and CCD, sites of nitric oxide synthase expression, suggests that it can regulate the effects of epithelial generated NO [11] . Also the localization of NADPH oxidase in the interstitial cells has been suggested to play a role as an oxygen sensor in the regulation of erythropoietin release [13] . Nox3 is described only in the fetal kidney [14] and its function remains uncertain.
ANGIOTENSIN II ACTIVATION OF NADPH OXIDASE
Griendling et al. first reported NADPH oxidase regulation by angiotensin (Ang)II in vascular smooth muscle cells [15] . We confirmed in the kidney that NADPH oxidase activation is dependant on AngII action on AT 1 receptor and the blockade of AT 1 receptor was shown to reduce p47phox expression and O 2 -production in the kidney [12] while blockade of AT 2 receptor enhanced the expression of p22phox and Nox1 and upregulated p67phox expression. [16] . Therefore, AT 1 receptor activation has a pro-oxidant effect and AT 2 activation has an anti-oxidant effect [17] . Stimulation of AT 1 receptor will lead to the activation of phospholipase D, protein kinase C (PKC), p38 mitogenactivated protein kinase (MAPK) and c-Src tyrosine kinase stimulating the phosphorylation of p47phox. Once phosphorylated, p47phox translocates to the membrane where it will bind to the membrane component, cytochrome b558, through its two Src-homology 3 (SH3) domains. Activation of c-Src also promotes the transactivation of epidermal growth factor receptor which leads to activation of phosphatidylinositol 3-kinase (PI3K) and Rac-1. Rac-1 then translocates to the membrane and keeps the enzyme complex activated [3, 4] . Fig. 1 depicts the activation cascade of NADPH oxidase system.
NADPH OXIDASE IN HYPERTENSION
NADPH oxidases have been proved important in the pathogenesis of renal damage in models of hypertension.
Fig. (1). NADPH oxidase components, mechanism of activation and sites of therapeutic target in renal damage via oxidative stress.
Angiotensin II stimulates AT 1 receptor triggering the events that will lead to phosphorylation of p47phox and assembly of the cytoplasmic components of NADPH oxidase to membrane components and formation of superoxide anion (O 2 .-). O 2 .-is transformed to H 2 O 2 by superoxide dismutase (SOD) or can react with NO forming ONOO -. Angiotensin converting enzyme inhibitors (ACEI) and AT 1 receptor blockers (ARB) prevent the activation of angiotensin AT 1 receptor, therefore, block this pathway in NADPH oxidase activation. Apocynin interferes with the assembly of NADPH oxidase cytosolic subunit p47phox and membrane subunits. Tempol is a membrane permeable SOD. Gliclazide scavenges O 2 .-via its azabicyclo-octyl ring structure and reduces macrophage infiltration in the kidney. Upregulation of p47phox subunit is seen in the kidneys of SHR which is a model of AT 1 -receptor dependent oxidative stress [11] . In this model we observed that p47phox expression is increased in the kidney of four week old SHR suggesting a role of ROS derived from NADPH oxidase in the development of high blood pressure. Previously - formation in the kidney of SHR and a reduction in blood pressure and renal vascular resistance with the administration of the membrane permeable superoxide dismutase (SOD) mimetic tempol [18, 19] . In the Dahl salt-sensitive model of hypertension with heart failure we found increased levels of renal AngII after the development of heart failure that stimulated NADPH oxidase expression and ROS formation [20] . The administration of an ACEI improved glomerular damage, arteriolosclerosis and proteinuria without effect on blood pressure demonstrating the importance of blockade of local AngII, and consequent decrease in NADPH oxidase expression and ROS production for organ protection [20] . Kawada et al. demonstrated in a mouse model of AngII slow-pressor-response, an increase in renal vascular resistance and blood pressure over 12 days, accompanied by an enhanced excretion of 8-iso-prostaglandin F 2α . Coinfusion of tempol to metabolize O 2 .-corrected the oxidative stress and prevented the rise in renal vascular resistance and blood pressure [21] . These data relate renal vasoconstriction and hypertension with enhanced generation of O 2 .
-in animal models of AngII-dependent hypertension, and demonstrate the beneficial effect of O 2 .-scavenge and NADPH oxidase decrease in the hypertensive kidney.
NADPH OXIDASE IN DIABETES MELLITUS
Hyperglycemia induces activation of PKC, formation of advanced glycation end-products, sorbitol accumulation and NF-κB activation [22] . PKC activation stimulates membranous translocation of NADPH oxidase subunits p47phox and p67phox resulting in ROS generation [23] .
ROS induce an inflammatory state and endothelial dysfunction that lead to the development of diabetic complications. In coronary arteries of diabetic pigs oxidative stress via NADPH oxidase led to an inflammatory state of increased expression of interleukin (IL)-6, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1 and vascular adhesion molecule (VCAM)-1. All these inflammatory mediators were down regulated by inhibitors of NADPH oxidase and suppression of O 2 .-formation [24] . Another study showed that prolonged exposure of human endothelial cells to high glucose increased endothelial nitric oxide synthase (eNOS) expression and NO release [25] , however, these increases were associated with a marked concomitant increase of O 2 .-production via NADPH oxidase [26] , leading to an imbalance between NO and O 2 .-, and a decrease in NO bioavailability [25] that could be prevented by NADPH oxidase blockade [26] . These data implicate the potential importance of blockade of NADPH oxidase in the inflammatory response and functional NO deficiency in diabetes.
In our studies we showed that in the early phase of diabetic nephropathy in rats there is an increase in the expression of NADPH oxidase subunit p47phox, the component responsible for the enzyme activation, and an increase in eNOS expression in the kidney [12, 27, 28] however without increase in cGMP due to NO scavenge by the increased O 2 .-and formed ONOO - [27] . These changes were followed by oxidation of lipids, nitrosylation of proteins and albuminuria that were ameliorated by down regulation of NADPH oxidase expression [12, 27, 28] . AT 1 dependency of NADPH oxidase activation in diabetic nephropathy could be observed by the decrease in p47phox expression in the kidney with administration of an ACEI or an ARB that reduced radical formation in the kidney and reduced albuminuria [12] . The combination of ACEI and dipyridamole, an inhibitor of cGMP phosphodiesterase (PDE) that enhances the action of NO, reduced urinary albumin excretion more effectively to the control level than ACEI alone conforming that improvement in NO bioavailability by O 2 .-blockade and increase in eNOS expression have a beneficial effect in diabetes [27] .
Administration of high cholesterol diet to diabetic rats additively increased renal expression of NADPH oxidase p47phox and O 2 .-production and decreased eNOS and SOD with enhanced intercellular adhesion molecule (ICAM)-1 expression and macrophage infiltration in the glomeruli [28] . As macrophage derived O 2 .-participates in the pathogenesis of atherosclerosis [29] , it is possible that the highly active macrophage NADPH oxidase contributed to kidney damage seen in this model of diabetes associated with hypercholesterolemia. The administration of gliclazide, the only sulfonylurea with antioxidant properties, resulted in reduction of NADPH oxidase expression in the kidney with decreased macrophage infiltration in glomeruli, and enhanced SOD and eNOS expression.
NO BIOAVAILABILITY AND ENOS UNCOUPLING BY NADPH OXIDASE
In hypertension, hypercholesterolemia and diabetes NADPH oxidase is over expressed and will generate O 2 .-in amounts that surpasses the handling capacity of the endogenous antioxidant system. One important interaction is between O 2 .-and NO generating ONOO -that will cause oxidation of eNOS cofactor tetrahydrobiopterin (BH 4 ) leading to a condition of eNOS uncoupling. The uncoupled eNOS generates O 2 .-rather than NO because under uncoupling condition electron is transferred to oxygen and not to L-arginine [30, 31] .
In models of glomerulonephritis eNOS expression is decreased and blockade of eNOS with L-NAME or eNOS gene knockout caused increased glomerular infiltration of monocytes, fibrin deposition and thrombus formation as well as decrease in glomerular filtration rate, therefore, eNOS is considered to have a renoprotective action [32] [33] [34] . In the chronic renal failure model, eNOS was also decreased and NADPH oxidase gp91phox was enhanced with reduction of SOD, thus, NO bioavailability was decreased [35] . Administration of SOD mimetic recovered NO bioavailability and reduced blood pressure in this model [35] . As decrease in eNOS and NO bioavailability is a common pathogenesis in renal damage it is postulated that increase in eNOS expression can be a strategy for renal protection. The eNOS transgenic mouse showed enhanced neo-vascularization in the ischemic-injured muscle in the lower extremities compared to wild mouse. Contrary, eNOS transgenic apoE knock out mouse revealed enhanced atherosclerotic aortic lesions compared to apoE knock out mouse [36] . The explanation for this is that activation of NADPH oxidase leads to oxidation of BH 4 and eNOS uncoupling generating O 2 .-rather than NO [31, 36] . As suggested by these lines of evidence in muscle and aorta, the renoprotective effect of eNOS may not be simply obtained by its over-expression, it is necessary to inhibit NADPH oxidase at the same time to suppress formation of ONOO -that will oxidize BH 4 to BH 2 . We have revealed that eNOS dimerization was decreased in the kidney of ischemia reperfusion injury, and BH 4 administration reversed eNOS coupling and prevented acute renal failure [37] . The inhibition of NADPH oxidase and BH 4 administration are important strategies to enhance the organ protective effect of eNOS in various disease conditions.
NADPH OXIDASE AS A THERAPEUTIC TARGET FOR RENAL PROTECTION
The renoprotective effect of ACEI and ARB are wellknown and ascribed not only to their hemodynamic effect and hormonal effect on mesangial cells but also to the inhibition of NADPH oxidase and the reduction of oxidative stress. Furthermore, on the line of renin-angiotensinaldosterone system, aldosterone also revealed to stimulate NADPH oxidase [38, 39] and its blockade by spironolactone or eplerenone reduced oxidative stress and showed a renoprotective effect [38] .
As NADPH oxidase activity is regulated not only by angiotensin II but also by IL-1β and TNF-α [15, 40] , the regulation of pro-inflammatory cytokines may be an important strategy to reduce oxidative stress. A selective p38MAPK-inhibitor, FR167653, inhibited IL-1β and TNF-α . Recently, it has been shown that p38 MAPK and ERK phosphorylate NADPH oxidase cytosolic components, p47phox and p67phox, and translocate them to the membrane component, cytochrome b558 [44] [45] [46] . p38 MAPK also enhances the exocytosis of cytochrome b558-containing granules to the cell membrane and increases NADPH oxidase activity [47] . Selective p38 MAPK inhibitors could be a therapeutic strategy in various renal diseases with enhanced oxidative stress, (Fig. 1) .
Apocynin is a methoxy-substituted catechol from the medicinal herb Picroria kurroa, and it inhibits NADPH oxidase by impeding the assembly of p47phox and p67phox subunits with NADPH oxidase membrane subunits [48] . Apocynin has an organ-protective effect in models of rheumatoid arthritis, inflammatory bowel disease, ischemic reperfusion lung injury, and respiratory muscle dysfunction in sepsis [49] [50] [51] [52] [53] where it inhibits the neutrophil oxidative burst and the generation of cytokines including TNF-α, IL-1β, IFN-γ, IL-4, and IL-10 [49, 52, 53] . The effect of apocynin in the kidney has not been fully investigated, and it is a possible potential drug that directly regulates NADPH oxidase activity, (Fig. 1) .
In conclusion, enhanced oxidative stress via NADPH oxidase is a common pathological pathway in renal damage in hypertension, diabetes, hypercholesterolemia as well as glomerulonephritis and renal failure. NADPH oxidase inhibition and increase in NO bioavailability are important therapeutic concepts to prevent renal damage in various diseases.
